LT3299377T - Struktūrizuoto polipeptido specifiškumo moduliavimas - Google Patents
Struktūrizuoto polipeptido specifiškumo moduliavimasInfo
- Publication number
- LT3299377T LT3299377T LTEP17188298.8T LT17188298T LT3299377T LT 3299377 T LT3299377 T LT 3299377T LT 17188298 T LT17188298 T LT 17188298T LT 3299377 T LT3299377 T LT 3299377T
- Authority
- LT
- Lithuania
- Prior art keywords
- modulation
- polypeptide specificity
- structured polypeptide
- structured
- specificity
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1117408.3A GB201117408D0 (en) | 2011-10-07 | 2011-10-07 | Modulation of structure polypeptide specificity |
GBGB1205612.3A GB201205612D0 (en) | 2012-03-29 | 2012-03-29 | Modulation of structured polypeptide specificity |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3299377T true LT3299377T (lt) | 2021-03-25 |
Family
ID=47080465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP17188298.8T LT3299377T (lt) | 2011-10-07 | 2012-10-08 | Struktūrizuoto polipeptido specifiškumo moduliavimas |
Country Status (21)
Country | Link |
---|---|
US (3) | US9994617B2 (lt) |
EP (2) | EP2764140B1 (lt) |
JP (3) | JP6254527B2 (lt) |
CN (1) | CN103906865B (lt) |
AU (1) | AU2012320407B2 (lt) |
BR (1) | BR112014008156A2 (lt) |
CA (1) | CA2849948C (lt) |
CY (1) | CY1123865T1 (lt) |
DK (1) | DK2764140T3 (lt) |
ES (1) | ES2650625T3 (lt) |
HK (1) | HK1252864A1 (lt) |
HR (1) | HRP20210394T1 (lt) |
HU (1) | HUE053389T2 (lt) |
LT (1) | LT3299377T (lt) |
NO (1) | NO2764140T3 (lt) |
PL (1) | PL2764140T3 (lt) |
PT (1) | PT2764140T (lt) |
RU (2) | RU2631931C2 (lt) |
SG (1) | SG11201400888TA (lt) |
SI (1) | SI3299377T1 (lt) |
WO (2) | WO2013050615A1 (lt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2631931C2 (ru) * | 2011-10-07 | 2017-09-28 | Байсикл Терапьютикс Лимитед | Модуляция специфичности структурированных белков |
EP2850095B1 (en) | 2012-05-17 | 2019-10-09 | RA Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
GB201306623D0 (en) * | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
ES2715379T3 (es) | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
SI3215518T1 (sl) * | 2014-10-29 | 2021-08-31 | Bicyclerd Limited | Biciklični peptidni ligandi, značilni za MT1-MMP |
WO2017124066A1 (en) * | 2016-01-14 | 2017-07-20 | Arrowhead Pharmaceuticals, Inc. | Method of modifying a peptide |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
EP3544621A1 (en) | 2016-11-27 | 2019-10-02 | BicycleRD Limited | Methods for treating cancer |
KR20190126294A (ko) * | 2016-12-23 | 2019-11-11 | 바이사이클티엑스 리미티드 | Mt1-mmp에 대한 결합용 펩티드 리간드 |
WO2018115203A1 (en) * | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
CN110366434B (zh) * | 2017-02-02 | 2022-04-05 | 阿克伦大学 | 使用镁催化剂通过开环聚合制备的官能化聚(富马酸丙烯酯)聚合物 |
EP3585420A4 (en) | 2017-02-22 | 2021-04-07 | Bioincept LLC | PEPTIDES AND METHODS OF TREATMENT OF DYSTROPHY RELATED CONDITIONS USING THEM |
US10899798B2 (en) * | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
EP4082557A3 (en) | 2017-07-17 | 2023-01-25 | Bioincept LLC | Peptides and methods of transplantation and restorative organ function |
EP3668887A1 (en) * | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
CN108191955B (zh) * | 2018-01-11 | 2020-05-19 | 中国科学院化学研究所 | 一种肽两亲分子及其制备方法与应用 |
CA3095582A1 (en) * | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
GB201808835D0 (en) * | 2018-05-30 | 2018-07-11 | Bicyclerd Ltd | Ligands and methods of selecting binding targets for such |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
EP3849615A1 (en) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
WO2020056198A2 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
CN109627301B (zh) * | 2019-02-18 | 2022-08-05 | 浙江新银象生物工程有限公司 | Nisin固体稳定剂开发及应用 |
US20220267379A1 (en) * | 2019-07-15 | 2022-08-25 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel inhibitors of kallikrein proteases and uses thereof |
TW202118770A (zh) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
CN114667134A (zh) | 2019-08-15 | 2022-06-24 | 希沃尔拜克治疗公司 | 苯并氮杂䓬缀合物的制剂及其用途 |
JP2022551607A (ja) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2145233C1 (ru) * | 1990-07-02 | 2000-02-10 | Дзе Аризона Борд оф Риджентс | Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом |
DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
US20030166003A1 (en) | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
WO2005122379A2 (en) * | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
US7863239B2 (en) | 2005-01-24 | 2011-01-04 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
PL2374472T3 (pl) | 2006-03-16 | 2018-11-30 | Dyax Corp. | Kompozycje i sposoby leczenia zaburzeń okulistycznych |
CA2659225A1 (en) * | 2006-07-26 | 2008-01-31 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
EP2742150A1 (en) | 2011-08-09 | 2014-06-18 | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg | A method of analysing a blood sample of a subject for the presence of a foetal disease or condition marker |
RU2631931C2 (ru) | 2011-10-07 | 2017-09-28 | Байсикл Терапьютикс Лимитед | Модуляция специфичности структурированных белков |
GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
ES2715379T3 (es) | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
-
2012
- 2012-10-08 RU RU2014118461A patent/RU2631931C2/ru active
- 2012-10-08 PL PL12778672T patent/PL2764140T3/pl unknown
- 2012-10-08 BR BR112014008156A patent/BR112014008156A2/pt not_active Application Discontinuation
- 2012-10-08 ES ES12778672.1T patent/ES2650625T3/es active Active
- 2012-10-08 CN CN201280049406.8A patent/CN103906865B/zh active Active
- 2012-10-08 RU RU2017132824A patent/RU2745572C2/ru active
- 2012-10-08 HU HUE17188298A patent/HUE053389T2/hu unknown
- 2012-10-08 DK DK12778672.1T patent/DK2764140T3/en active
- 2012-10-08 EP EP12778672.1A patent/EP2764140B1/en active Active
- 2012-10-08 WO PCT/EP2012/069897 patent/WO2013050615A1/en active Application Filing
- 2012-10-08 JP JP2014533945A patent/JP6254527B2/ja active Active
- 2012-10-08 AU AU2012320407A patent/AU2012320407B2/en active Active
- 2012-10-08 SG SG11201400888TA patent/SG11201400888TA/en unknown
- 2012-10-08 US US14/350,263 patent/US9994617B2/en active Active
- 2012-10-08 CA CA2849948A patent/CA2849948C/en active Active
- 2012-10-08 PT PT127786721T patent/PT2764140T/pt unknown
- 2012-10-08 NO NO12778672A patent/NO2764140T3/no unknown
- 2012-10-08 SI SI201231892T patent/SI3299377T1/sl unknown
- 2012-10-08 WO PCT/EP2012/069898 patent/WO2013050616A1/en active Application Filing
- 2012-10-08 LT LTEP17188298.8T patent/LT3299377T/lt unknown
- 2012-10-08 US US14/350,192 patent/US10800813B2/en active Active
- 2012-10-08 EP EP17188298.8A patent/EP3299377B1/en active Active
-
2017
- 2017-07-31 JP JP2017147687A patent/JP6568161B2/ja active Active
-
2018
- 2018-09-21 HK HK18112198.5A patent/HK1252864A1/zh unknown
-
2019
- 2019-08-01 JP JP2019142001A patent/JP6906571B2/ja active Active
-
2020
- 2020-06-11 US US16/899,192 patent/US11912794B2/en active Active
-
2021
- 2021-02-26 CY CY20211100165T patent/CY1123865T1/el unknown
- 2021-03-08 HR HRP20210394TT patent/HRP20210394T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252864A1 (zh) | 結構化多肽特異性的調控 | |
HUS1900001I1 (hu) | Transztiretin expressziójának módosítása | |
HRP20181440T1 (hr) | Retinoidni liposomi, namijenjeni poboljšavanju moduliranja eksprimiranja hsp47 | |
HK1221172A1 (zh) | 結構化多肽特異性的調控 | |
HK1201555A1 (en) | Antisense modulation of gccr expression gccr | |
EP2595664A4 (en) | MODULATION OF NUCLEAR RETENTION RNA | |
HK1207078A1 (en) | Inhibition of enzymes | |
IL227656A0 (en) | Immunoglobulin site engineering | |
ZA201403108B (en) | Purification of anti-c-met antibodies | |
EP2864479A4 (en) | MODULATION OF UBE3A-ATS EXPRESSION | |
EP2776564A4 (en) | MODULATION OF TMPRSS6.EXPRESSION | |
PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
IL228773B (en) | Antisense modulation of b1ptp expression | |
EP3560952C0 (en) | VARIANT OF BPIFB4 PROTEIN | |
EP2625280A4 (en) | MODULATION OF VSEL-TYPE STEM CELLS BY IGF-1 | |
GB201117408D0 (en) | Modulation of structure polypeptide specificity | |
GB201205612D0 (en) | Modulation of structured polypeptide specificity | |
HK1201420A1 (en) | Use of amylase enzyme |